| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:3508472 | IVR | 20000 mg/L | - | No significant effects observed | - |
| IVR | 40 mg/L | 40 mg/L | Reduced glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/L | 40 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 40 mg/L | 40 mg/L | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| PMID:7233432 | IVR | 0.5 mg/L | 0.5 mg/L | Increased beta-glucuronidase levels | Metabolic endocrine-mediated perturbations |
| IVR | 5 mg/L | 5 mg/L | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:7292493 | IVR | 5 mg/L | 5 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/L | 40 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.